 | |
| Company type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2013[1] |
| Headquarters | Seattle, WA |
Key people | Hans Bishop (CEO & President) Steve Harr, M.D. (CFO) |
| Parent | Bristol-Myers Squibb |
| Website | www |
Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.[1] The company raised $300 million through private funding and a further $265 million through their IPO.
On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion.[2]
In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene.[3]
- ^ a b "News Release". Juno Therapeutics.
- ^ Lombardo, Cara (2018-01-22). "Celgene to Buy Juno Therapeutics for $9 Billion". Wall Street Journal. ISSN 0099-9660. Retrieved 2018-01-22.
- ^ Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company, PM BMS, November 20, 2019; retrieved May 20, 2020
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search